Back to top

crispr: Archive

Sundeep Ganoria

CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?

The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.

VRTXPositive Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change

Zacks Equity Research

CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

ALNYPositive Net Change BMRNPositive Net Change VRTXPositive Net Change CRSPPositive Net Change

Sundeep Ganoria

CRISPR Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.

VRTXPositive Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change

Sundeep Ganoria

CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?

The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.

VRTXPositive Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change

Zacks Equity Research

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.

EDITPositive Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change